| Species |
Human |
| Protein Construction |
DNAM-1/CD226 (Glu19-Asn247)
Accession # Q15762 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by SECHPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized DNAM-1/CD226, His & Avi, Human at 5μg/ml (100μl/well) on the plate can bind Human CD155, mFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
28.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 45-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein in the immunoglobulin superfamily.DNAM-1 mediates cellular adhesion to other cells bearing its ligands, CD112 and CD155, and cross-linking DNAM-1 with antibodies causes cellular activation. Furthermore, DNAM-1 can interact with PVR and PVRL2. |
| Synonyms |
CD226 molecule; CD226; DNAM1; PTA1; TLiSA1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
